Recursion Pharmaceuticals, Inc. (RXRX) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Recursion Pharmaceuticals, Inc. (RXRX) Profile & Business Summary
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Key Information
| Ticker | RXRX |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.recursion.com |
Market Trend Overview for RXRX
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-11-06 (ET)
As of 2026-11-06, RXRX is moving sideways with low volatility. Over the longer term, the trend remains bullish.
RXRX last closed at 3.52. The price is about 1.6 ATR below its recent average price (3.83), and the market is currently in a sideways market with low volatility. Price at 3.52 is moving between light support near 3.44 and light resistance near 3.63. Direction remains unclear. View Support & Resistance from Options
Price is moving in a tight range. This often leads to a stronger move once the range breaks, increasing one-sided risk.
Trend score: 40 out of 100. Overall alignment is unclear. The market is currently in a sideways phase with tightening price movement. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside risk boundary is near 3.02. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-10-28, reflecting a technical shift toward positive directional alignment.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
Some late-day positioning was observed, but it lacked strong overnight commitment.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not deploy this setup because predictability is still too low, internal signals are not aligned strongly enough, price is still close to a gamma transition zone, there is meaningful next-session pullback or digestion risk, and the setup already looks stretched. Predictability is 6%, agreement is 29%, and reversal risk is 43%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 48 trading days, with turnover-based decay. The sample period is 2026-09-01 to 2026-11-06. The current price is 3.52, 10.74% below the estimated average cost of 3.94. An estimated 9.2% of recent positioning is below the current price, while 89.4% is above it. The peak-density price is 3.83. The largest concentrated cost region is 3.72 to 4.08 and contains 36.9% of the estimated distribution. The current price is within the 3.49 to 3.69 cost region. The nearest region above the current price is 3.72 to 4.08.
Short Interest & Covering Risk for RXRX
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is well above normal levels, increasing the risk of forced covering and sudden price moves. (Historical percentile: 83%)
Structure Analysis
RXRX Short positioning looks normal. Current days to cover is 4.4 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. Price is already trending lower (20D return -19.3%). The current configuration reflects active downside pressure rather than latent structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
In the latest reporting period, short interest continues to increase. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 1× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-10-15 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.